PharmaceuticalsHolly Springs, North CarolinaAnnouncement date · Apr 11, 2024

Holly Springs Second-Phase Cell Culture Manufacturing Expansion (2024 Phase)

See all projects by FUJIFILM Biotechnologies →

$1.2 billion second-phase expansion of FUJIFILM Biotechnologies' (formerly FUJIFILM Diosynth Biotechnologies — the legal entity name used in the original 2021 and 2024 announcements, rebranded FUJIFILM Biotechnologies on June 2, 2025) Holly Springs, North Carolina cell culture campus, announced April 11, 2024. It adds two production modules with eight additional 20,000-liter bioreactors — doubling total site capacity to sixteen bioreactors — and 680 new highly skilled jobs (average salary approximately $110,000), with hiring beginning in 2027 and running through 2031. Expansion capacity is scheduled to come online in early 2028; argenx was named in September 2025 as the first confirmed second-phase tenant, with FUJIFILM to manufacture drug substance for efgartigimod at the site starting in 2028. Separately tracked from the 2021 first-phase facility. AFT records only the incremental $1.2 billion and 680 jobs; the original $2 billion / 725 jobs, the cumulative more-than-$3.2 billion campus total, and FUJIFILM's rounded ~1,400-jobs-by-2031 campus goal are excluded from these figures to prevent double counting. Job-figure reconciliation: AFT preserves the itemized incremental announcements — 725 (by end-2028) plus 680 (by 2031) = 1,405 — and treats FUJIFILM's later '1,400 by 2031' language as a rounded campus goal rather than a separate or superseding commitment. Customer capacity commitments hosted at the campus (Johnson & Johnson $2B/10-year, Regeneron $3B/10-year and argenx) are supplier agreements excluded from FUJIFILM facility investment; construction jobs and public incentives are also excluded.

Investment
$1.20B
Permanent jobs announced
680
Status
Under Construction
Expected opening
2028
Why this project qualifies

With $1.2 billion in facility-specific investment and 680 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). It is also confirmed by official public sources and involves a physical manufacturing facility in the United States.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
FUJIFILM Biotechnologies (Second-Phase Expansion)
Industry
Pharmaceuticals
Location
Holly Springs, North Carolina
Investment
$1.20B
Permanent jobs announced
680
Status
Under Construction
Announced
Apr 11, 2024
Expected opening
2028
Added to tracker
Sep 1, 2026
Sources

Official references

Cite this project

American Factory Tracker. "Holly Springs Second-Phase Cell Culture Manufacturing Expansion (2024 Phase) — FUJIFILM Biotechnologies, Holly Springs, NC." https://americanfactorytracker.com/projects/fujifilm-diosynth-biotechnologies-holly-springs-expansion. Accessed November 3, 2026.

Please also cite the original sources listed above for underlying figures.

Back to the tracker/projects/fujifilm-diosynth-biotechnologies-holly-springs-expansion

Follow America's Industrial Growth

New industrial projects, permanent manufacturing jobs, and progress across the country, delivered in the AFT Briefing, our free newsletter.

GET THE AFT BRIEFING